page full analyst note
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim sep
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
myriad acquisit divestitur past decad
constant state evolut
firm transform reduc exposur cyclic market
increas focu environment human health offer
nonstop busi shuffl yet produc sustain return
capit invest competit posit
certainli shift better though sever attract
avenu growth reach particularli emerg market firm
could final produc tangibl benefit sharehold
view neonat screen busi crown jewel
product portfolio firm hold lead posit
neonat prenat matern test screen bulk
babi test world-wide market character
stabl profit price power yet main opportun
newborn screen busi lie oversea emerg market
half chines newborn screen
kit major undergo test three four
disord compar disord firm
capit vast potenti market along
india latin america emerging-market opportun also
abound firm infecti diseas product line
environment segment grow emphasi qualiti life
segment posit benefit strong secular
demand emerging-market revenu expect
shift revenu mix toward diagnost area help lessen
exposur low-margin industri end market
offer better growth profil think futur valu creation
conting greater disciplin firm capital-alloc
strategi -- strongest suit past compani
taken step shed weak asset support attract
diagnost acquisit includ billion euroimmun
purchas remain skeptic enough valu
creation justifi level invest year
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
provid instrument consum servic
pharmaceut biomed chemic environment gener
industri market compani oper two segment diagnost
includ prenat screen infecti diseas test
discoveri analyt solut compos life scienc industri
environment food applic offer product
servic rang genet screen environment analyt tool
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
broadli meet expect retain
per share fair valu estim firm
impress expand adjust oper margin
gener earn per share
exceed capit iq consensu revenu grew
million fall short million
consensu although headwind appli market
slowdown diagnost segment hinder revenu
growth believ revenu miss materi
chang view compani long-term prospect
growth year year diagnost firm experienc
quarterli organ revenu growth year year
driven continu strength euroimmun tulip
declin sequenti though hurt headwind
unfavor foreign exchang rate consolid
genom test laboratori brandford pittsburgh
discoveri analyt solut segment produc
organ revenu growth year year driven
increas food cannabi demand
meizheng group addit believ
abl better encapsul broad-bas growth food
servic recent acquisit expand firm
total address market approxim billion
manag slightli rais outlook increas
higher end ep estim per share
previous estim alreadi line new
outlook improv oper leverag
offset unfavor headwind continu
face remaind fiscal year
notabl firm deal sever
organiz chang near futur plan
ceo chang integr meizheng group
acquisit consolid effort suppli chain
vari structur realign simplif
process suspect firm may abl gener
higher return target market eventu
increas fair valu estim per share
reflect recent gener cash flow
valuat impli adjust price-to-earnings multipl
expect revenu growth
driven mostli compani diagnost busi
newborn screen
remain healthi addit growth compani
euroimmun acquisit add increment benefit
compani diagnost channel forecast
discoveri analyt solut segment post
low-single-digit organ growth forecast period
furthermor chines emerg market demand
analyt instrument bolster firm
environment industri busi
compani growth margin return invest
capit profil improv sale medic
imag busi anticip improv global
posit optim infrastructur continu
boost firm adjust oper margin toward
manag target even improv
oper margin remain lower end
life scienc space averag five-year return
capit hover near model assum
compani weight averag cost capit
stabil gain divers product line
rel stabl end market partial off-set potenti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
sale slightli break-even level scenario
believ overal busi possess
econom moat firm competit posit
discoveri analyt solut approxim
perkin busi close euroimmun deal
weaker peer depress outlook
although compani tie higher-end academ
pharmaceut end market space overrun
entrench larger player like agil thermo fisher
bode well current suit
instrument result return invest capit
struggl cover cost past sale
weak medic imag busi significantli improv
compani foot wed like see consist
posit capit alloc decis award
diagnost busi amount roughli
revenu approxim revenu close
euroimmun deal provid differ stori
well-establish nich newborn screen compani
appli tandem mass spectrometri ms/m
newborn screen market earli thank well-tim
partnership leader mass spectrometri
ms/m standard newborn screen use
measur multipl molecul significantli
reduc test time cost allow analysi
chemic level combin rather isol
intangibles-includ firm extens test menu
technolog expertis
establish relationship govern hospit -- increas
barrier entri
razor-and-blad model newborn screen busi
make custom hesit switch provid
compani test perform major -born
babi rapidli expand newborn popul
space
technolog disrupt emerging-market risk
rang outcom compani start per share
bear case per share optimist bull
scenario one main concern includ firm abil
creat strateg value-enhanc growth emerg
market maintain profit face
persist tough price macroeconom environ
bull-cas scenario revenu growth driven
diagnost segment assum acceler growth
emerging-market region along solid newborn
screen menu expans adopt shift product
posit impact gross margin signific margin
expans would posit compani close
peer conting upon superb execut
bear-cas scenario assum macroeconom
challeng weigh industri academ sale
next coupl year push revenu growth
annual next five year also assum
forc accept price concess order
maintain market share temper environment health
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
water agil better equip compet price
technolog capabl
disrupt innov genom sequenc could
also upset compani otherwis solid newborn
screen busi futur howev think
enough time industri
proactiv reposit near term compani
stand benefit growth newborn screen
emerg market number mandat test
util rate expand correspond barrier
entri cheap indigen manufactur larg
multi-national player would consid upgrad
moat trend posit given market share take-over
discoveri analyt segment compani focus
capit expenditur toward diagnost unit
outweigh no-moat part busi
emerg market particularli china brazil longer
ramp-up process india may lead slower growth
firm achiev china howev
repres sale approxim
post-euroimmun augment diagnost segment
parent pay annuiti store child stem cell
chanc cell necessari treatment later
life creat stabl revenu sourc
virtual prohibit regulatori barrier privat
bank industri reput paramount stem cell
storag busi parent highli sensit qualiti
servic consid potenti life-sav viacord
wide recogn formid player space
industri statist impli low chanc babi
benefit bank cell continu advanc
stem cell therapi offer potenti capabl
self-bank stem cell futur
even share diagnost revenu increas
segment repres major
addit manag histor
deploy capit bolt-on acquisit mani tuck
no-moat segment littl build firm
competit advantag opinion
view overal moat trend stabl
advantag opinion discoveri analyt
discoveri segment primarili cater industri
commerci user sensit price rather
increment product sophist favor secular
demand kept busi afloat seem
littl stop competitor steal market
share bigger player impress margin like
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
well-entrench nich newborn
screen stand benefit grow adopt
menu expans emerg market particularli
odevelop countri face grow pressur
improv air water qualiti
lead provid environment test instrument
well posit profit secular trend
orec initi improv oper
effici dramat expand firm margin
sinc way go
financi statement past
litter numer
decad
myriad
restructur charg result
acquisit disposit
state
acquisit firm keep financi
oth compani profit among lowest
industri larg due sub-optimal oper
oth analyt instrument space extrem
crowd littl stop competitor steal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
think carri manag debt load
histori consist acquisit tend keep financi
leverag elev exampl part billion
euroimmun acquisit manag ad
million debt still believ focal
strategi compani continu expand
presenc diagnost emerg market perkinelm
pay small dividend given indic
will increas pay-out ratio near futur
adjust free
gener
gener revolv adjust
commit
potenti technolog disrupt emerging-market
risk partial off-set stabil gain compani
divers product line rel stabl end market
investor risk overpay
overprun integr result
struggl gener above-cost return capit
past addit analyt instrument bulk
firm could easili lose share cheaper local
competitor larger intern player act
firm
success adapt strategi futur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
assign perkinelm poor stewardship rate
execut team -- led ceo robert friel sinc
shown pedestrian record far come
valu creation sharehold return compani
deploy free cash oper
increas debt level acquisit yet
produc meaning contribut return
favor strateg shift away cyclic product line
result nonetheless subpar particularli
compar mani peer analyt instrument
admittedli last recess cycl disrupt
strategi compani decad stagnant
oper margin half year
manag bare exceed cost capit includ
goodwil meanwhil dividend remain unchang
acquisit strategi continu appear expens
eye final regard account practic
remain discourag high frequenc muddi
segment reclassif recent year
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
